A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 225 participants.

Also called NCT01176240

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 225 participants (enrolled count) (from the registry)
Sponsor
Chelsea Therapeutics (from the registry)
Registry
  • NCT NCT01176240
Other papers using this trial's data
  • Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A) Journal of Parkinson's disease, 2014 DOI, PubMed 24326693

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01176240. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2014-05-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
Acronym
306A/306B
Condition
Parkinson's Disease
Intervention (Drug)
Droxidopa
Intervention (Other)
Placebo
Lead sponsor
Chelsea Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01176240
Content hash
9a6694232a2d657d8c5af717a53d80fec9e9fa450085336453153df0e306f12c